Passage BIO, Inc. is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. Its lead candidate, PBFT02, is an AAV1-based gene replacement therapy delivered via intra cisterna magna administration to elevate progranulin levels, targeting FTD-GRN, FTD-C9orf72, and potentially ALS and Alzheimer's disease. The company also has a preclinical Huntington's disease program through its collaboration with Gemma Biotherapeutics.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001104659-26-022549 | EDGAR | 91K words |
| 2025-03-04 | 2024-12-31 | 0001558370-25-002101 | EDGAR | 91K words |
| 2024-03-04 | 2023-12-31 | 0001558370-24-002310 | EDGAR | 86K words |
| 2023-03-06 | 2022-12-31 | 0001558370-23-002833 | EDGAR | 85K words |
| 2022-03-03 | 2021-12-31 | 0001558370-22-002719 | EDGAR | — |
| 2021-03-03 | 2020-12-31 | 0001558370-21-002287 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001104659-26-093021 | EDGAR | 29K words |
| 2025-11-10 | 2025-09-30 | 0001104659-25-109180 | EDGAR | 66K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011146 | EDGAR | 66K words |
| 2025-05-13 | 2025-03-31 | 0001558370-25-007489 | EDGAR | 64K words |
| 2024-11-13 | 2024-09-30 | 0001558370-24-015431 | EDGAR | 68K words |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011463 | EDGAR | 64K words |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008058 | EDGAR | 60K words |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018686 | EDGAR | 62K words |
| 2023-08-07 | 2023-06-30 | 0001558370-23-013489 | EDGAR | 60K words |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009256 | EDGAR | 58K words |
| 2022-11-10 | 2022-09-30 | 0001558370-22-017285 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012042 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-03 | 0001140361-26-035515 | EDGAR | 67K words |
| 2026-03-10 | 0001104659-26-025550 | EDGAR | 1K words |
| 2026-03-03 | 0001104659-26-022539 | EDGAR | 2K words |
| 2026-01-12 | 0001104659-26-002696 | EDGAR | 4K words |
| 2025-11-10 | 0001104659-25-109158 | EDGAR | 2K words |
| 2025-09-18 | 0001104659-25-091288 | EDGAR | 1K words |
| 2025-08-12 | 0001558370-25-011143 | EDGAR | 2K words |
| 2025-07-29 | 0001104659-25-071779 | EDGAR | 1K words |
| 2025-07-14 | 0001104659-25-067561 | EDGAR | 1K words |
| 2025-06-23 | 0001104659-25-061371 | EDGAR | 3K words |
120 total filings indexed. 92 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001787297 |
| Ticker | PASG |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.passagebio.com |
| Listed | 2020-02-28 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PASG (~200 tokens, structured JSON with cryptographic provenance)